CD4 and myasthenia gravis: Based on these results and prior studies, this research proposes that JYBP’s therapeutic mechanism in MG may involve inhibiting the differentiation of CD4+ T cells into Th17 cells via the TAK1/p38 MAPK/eIF-4E signaling pathway.